

THALLIUM IMAGING TEST FORM
(ETT/PERSANTINE/ADENOSINE)

Complete for each Thallium Imaging test performed. Send original to Thallium Core Lab and a copy to the Data Coordinating Center.

Clinic No.			-				
ID No.			-				
Form Type	T	T					

PART I: IDENTIFICATION

1. Patient's NAME CODE: -----

fm8fday

2. Date of study: -----

Month Day Year

3. Identify this test: ----- (1) (2) (3)

ETT Persantine Adenosine

idtest2

4. Time of test:

thaltyp2

- Pre-discharge or within 5 days after hospital discharge ----- (1)
- Six-week follow-up (42 to 70 days) ----- (2)
- Follow-up Thallium (71 to 182 days) ----- (3)
- Other ----- (4)

5. Was test performed according to protocol guidelines? ----- (1) (2)

protthal

Yes No



A. Reason: (Check one.)	thalreas
Complications post-revascularization -----	(1)
Clinical reason -----	(2)
Protocol violation -----	(3)
Other -----	(4)
Specify: _____	

ID No.			-				
--------	--	--	---	--	--	--	--

PART II: TESTING

6. Total dose of Thallium administered? ----- thaldos2 mCi

7. How long was exercise continued after injection of Thallium? ----- thalexer sec.

8. Was Persantine administered? ----- persadm
 (1) (2)
 Yes No
 ↓

A. Persantine infusion? ----- persinf (1) (2)
 Yes No
 ↓

1) Total dose ----- pinfdose mg

B. Oral Persantine? ----- persoral (1) (2)
 Yes No
 ↓

1) Total dose ----- podose mg

C. Was aminophylline given? ----- aminoph (1) (2)
 Yes No
 ↓

1) Total dose ----- amindose mg IV

9. Was Adenosine administered? ----- adenadm (1) (2)
 Yes No
 ↓

A. Total dose ----- adendose mg

B. Total infusion time ----- adentime seconds

ID No.			-					
Form Type	T	T						

10. Was nitroglycerin given? ----- thalng ----- (1) (2)
 Yes No
 ↓

A. Total dose: (Complete one.)	
1)	<u>thngiv</u> _____ mcg IV
2)	<u>thngsl</u> _____ mg SL

11. Which of the following Thallium imaging scans were obtained? (Answer each item.)

A. Immediate post-exercise ----- impost ----- Yes No
 (1) (2)

B. Delayed (2 to 2.5 hr) ----- imdelay ----- (1) (2)

C. Rest (24 hrs post exercise) ----- imrest ----- (1) (2)

ID No.			-					
Form Type	T	T						

PART III: DATA ON MAGNETIC TAPE

Complete necessary data in columns A through E.
 EX = Immediate D = delayed (2 to 2.5 hr)
 R = Rest (24 hrs) post-exercise

	A. <u>Order*</u> <u>on tape</u>	B. <u>Military Time</u> <u>hours:minutes</u>	C. <u>Duration</u> <u>(minutes)</u>	D. <u>Actual</u> <u>Obliquity (°)</u>	E. <u>Counts/View</u>
12. Field flood	___				
13. Bar phantom	___				
14. Injection site	___	___:___	15 sec		___ K
15. LAO EX (immediately Post EX)	___	___:___	___	___	___ K
16. LLAT EX	___	___:___	___	___	___ K
17. ANT EX	___	___:___	___	___	___ K
18. Breast marker LAO EX	___				
19. Breast marker LLAT EX	___				
20. Breast marker ANT EX	___				
LAO D (delayed 2-2.5 hr)	___	___:___	___	___	___ K
22. LLAT D	___	___:___	___	___	___ K
23. ANT D	___	___:___	___	___	___ K
24. Breast marker LAO D	___				
25. Breast marker LLAT D	___				
26. Breast marker ANT D	___				
27. LAO R (24 hr)	___	___:___	___	___	___ K
28. LLAT R	___	___:___	___	___	___ K
29. ANT R	___	___:___	___	___	___ K
30. Breast marker LAO R	___				
31. Breast marker LLAT R	___				
32. Breast marker ANT R	___				

*Use 00 if not done.

ID No.			-					
Form Type	T	T						




PART IV: VISUAL ANALYSIS

These data should only be interpreted from the exercise and 2 to 2 1/2 hour delayed imaging scans, not from the study performed 24 hours post exercise.

33. Enlarged, dilated heart? ----- (1) (2)
 Yes No

endihr

34. Visual segment analysis:

	<u>Fixed</u>	<u>Partial Redistri- bution</u>	<u>Complete Redistri- bution</u>	<u>Normal</u>	<u>Reverse Redistri- bution</u>	<u>Un inter- pretable</u>	
A. LAO:							
	1) Upper septum	(1)	(2)	(3)	(4)	(5)	(6) laous
	2) Lower septum	(1)	(2)	(3)	(4)	(5)	(6) laols
	3) Apex	(1)	(2)	(3)	(4)	(5)	(6) laoapx
	4) Inferolateral	(1)	(2)	(3)	(4)	(5)	(6) laoil
	5) Posterolateral	(1)	(2)	(3)	(4)	(5)	(6) laopl
B. ANT:							
	1) Anterobasal	(1)	(2)	(3)	(4)	(5)	(6) antab
	2) Anterolateral	(1)	(2)	(3)	(4)	(5)	(6) antal
	3) Apex	(1)	(2)	(3)	(4)	(5)	(6) antapx
	4) Apical septum	(1)	(2)	(3)	(4)	(5)	(6) antas
	5) Inferoseptal	(1)	(2)	(3)	(4)	(5)	(6) antis
C. LLAT:							
	1) Anterobasal	(1)	(2)	(3)	(4)	(5)	(6) llatab
	2) Anterior	(1)	(2)	(3)	(4)	(5)	(6) llatant
	3) Apex	(1)	(2)	(3)	(4)	(5)	(6) llatapx
	4) Inferior	(1)	(2)	(3)	(4)	(5)	(6) llatinf
	5) Posterobasal	(1)	(2)	(3)	(4)	(5)	(6) llatpb

ID No.			-						
Form Type	T	T							

35. Abnormal lung uptake? ----- **ablung** (1) (2)
 Yes No
 ↓

A. Abnormality: abamt Mild to Moderate (1) Severe (2)
--

36. Transient LV dilatation? ----- **tlbdilat** (1) (2)
 Yes No

37. Regions with reversible hypoperfusion: (Answer each item.)

<i>Only segments noted in Item 34 as having partial or complete redistribution should be counted.</i>

A. Anterior (B ₁ , B ₂ , C ₁ , or C ₂) -----	antisc	<u>Yes</u>	<u>No</u>
		(1)	(2)
B. Septum (A ₁ or A ₂) -----	sepisc	(1)	(2)
C. Lateral (A ₄ or A ₅) -----	laticsc	(1)	(2)
D. Inferoapical (A ₃ contiguous with A ₂) -----	iaisc	(1)	(2)
E. Inferior (B ₄ , B ₅ , C ₄ , or C ₅) -----	infisc	(1)	(2)
F. Non-contiguous apical (A ₃ , B ₃ , or C ₃) -----	apcisc	(1)	(2)
(Counted as separate region only if non-contiguous with other region(s) with reversible hypoperfusion.)			

38. High risk*:

A. Abnormal lung uptake (Question 35) and ≥ 1 region with reversible hypoperfusion (Question 37, at least 1 item answered YES) -----	alured	<u>Yes</u>	<u>No</u>
		(1)*	(2)
B. ≥ 2 regions with reversible hypoperfusion (Question 37, at least 2 items answered YES) -----	twoish	(1)*	(2)

*If A or B is answered YES, patient has reached a defined study end point.

ID No.			-					
Form Type	T	T						

PART V: TECHNICAL PROBLEMS

39. Did patient motion interfere with the study? ----- **motion** (1) (2)
 Yes No
 ↓

A. Which views? (Check all that apply.)

	a.	b.	c.
	EX	D	R
1) ANT -----	motant ^{EX} (1)	motant ^D (1)	motant ^R (1)
2) LAO -----	motlao ^{EX} (1)	motlao ^D (1)	motlao ^R (1)
3) LLAT -----	motllat ^{EX} (1)	motllat ^D (1)	motllat ^R (1)

40. Were there positioning difficulties? ----- **position** (1) (2)
 Yes No
 ↓

A. Which views? (Check all that apply.)

	a.	b.	c.
	EX	D	R
1) ANT -----	posant ^{EX} (1)	posant ^D (1)	posant ^R (1)
2) LAO -----	poslao ^{EX} (1)	poslao ^D (1)	poslao ^R (1)
3) LLAT -----	posllat ^{EX} (1)	posllat ^D (1)	posllat ^R (1)

41. Are there breast attenuation or other attenuation artifacts? ----- **breast** (1) (2)
 Yes No
 ↓

thalfem

A. Is patient female? ----- Yes (1) No (2)

PART VI: ADMINISTRATIVE MATTERS

42. Research Coordinator:

Signature: _____ T3 Staff No.: _____

43. Date form and diskette mailed to Thallium Core Lab: -----
 Month Day Year

ID No.			-					
Form Type	T	T						

T3 Form 8F: Variables from earlier revisions
[Revision 0 form not available]

IDTEST Revision 1 Item 3; Revision 2 Item 3
Identify this test:
1=ETT 2=Persantine

THALPER Revision 0 Item 5
Thallium or Persantine?
1=Thallium

THALLIUM Revision 0 Item 5A
Thallium 201 GI
1=Yes

THALTYPE Revision 1 Item 4
Time of test:
1=Pre-discharge or within 5 days of hospital discharge
2=Six-week follow-up
3=Other

IMAGE Revision 1 Item 10
Was Thallium imaging complete?
1=Yes 2=No

*T3B form8f**The CONTENTS Procedure*

Data Set Name:	WORK.FORM8F	Observations:	1622
Member Type:	DATA	Variables:	80
Engine:	V8	Indexes:	0
Created:	12:53 Friday, February 6, 2004	Observation Length:	344
Last Modified:	12:53 Friday, February 6, 2004	Deleted Observations:	0
Protection:		Compressed:	NO
Data Set Type:		Sorted:	NO
Label:			

----Alphabetic List of Variables and Attributes----					
#	Variable	Type	Len	Pos	Label
47	ABAMT	Num	4	164	f8Fq35A: Lung uptake abnormality
46	ABLUNG	Num	4	160	f8Fq35: Abnormal lung uptake
20	ADENADM	Num	4	72	f8Fq9: Adenosine
21	ADENDOSE	Num	5	321	f8Fq9A: Adenosine dose (mg)
22	ADENTIME	Num	5	326	f8Fq9B: Adenosine infusion time (secs)
55	ALURED	Num	4	196	f8Fq38A: Abnormal lung uptake & reversib
19	AMINDOSE	Num	5	316	f8Fq8C1: Aminophylline dose (mg IV)
18	AMINOPH	Num	4	68	f8Fq8C: Aminophylline
36	ANTAB	Num	4	120	f8Fq34B1: ANT analysis anterobasal
37	ANTAL	Num	4	124	f8Fq34B2: ANT analysis anterolateral
38	ANTAPX	Num	4	128	f8Fq34B3: ANT analysis apex
39	ANTAS	Num	4	132	f8Fq34B4: ANT analysis apical septum
40	ANTIS	Num	4	136	f8Fq34B5: ANT analysis inferoseptal
49	ANTISC	Num	4	172	f8Fq37A: Reversible hypoperfusion anteri
54	APCISC	Num	4	192	f8Fq37F: Reversible hypoperfusion non-co
77	BREAST	Num	4	284	f8Fq41: Breast attenuation
30	ENDIHRT	Num	4	96	f8Fq33: Enlarged heart
80	FM8FDAY	Num	8	16	f8Fq2: Days to study
2	FMTYP	Char	4	292	Form Type
52	IAISC	Num	4	184	f8Fq37D: Reversible hypoperfusion infero
3	IDTEST	Num	4	24	f8Fq3 (rev 0): Identify test
4	IDTEST2	Num	4	28	f8Fq3: Identify test

(06FEB04--12:53)

T3B form8f**The CONTENTS Procedure**

-----Alphabetic List of Variables and Attributes-----					
#	Variable	Type	Len	Pos	Label
26	IMAGE	Num	4	80	f8Fq10 (rev 0): Thallium imaging complet
28	IMDELAY	Num	4	88	f8Fq11B: Delayed scan
27	IMPOST	Num	4	84	f8Fq11A: Immed post-exercise scan
29	IMREST	Num	4	92	f8Fq11C: Rest scan
53	INFISC	Num	4	188	f8Fq37E: Reversible hypoperfusion inferi
33	LAOAPX	Num	4	108	f8Fq34A3: LAO analysis apex
34	LAOIL	Num	4	112	f8Fq34A4: LAO analysis inferolateral
32	LAOLS	Num	4	104	f8Fq34A2: LAO analysis lower Septum
35	LAOPL	Num	4	116	f8Fq34A5: LAO analysis posterolateral
31	LAOUS	Num	4	100	f8Fq34A1: LAO analysis upper septum
51	LATISC	Num	4	180	f8Fq37C: Reversible hypoperfusion latera
41	LLATAB	Num	4	140	f8Fq34C1: LLAT analysis anterobasal
42	LLATANT	Num	4	144	f8Fq34C2: LLAT analysis anterior
43	LLATAPX	Num	4	148	f8Fq34C3: LLAT analysis apex
44	LLATINF	Num	4	152	f8Fq34C4: LLAT analysis inferior
45	LLATPB	Num	4	156	f8Fq34C5: LLAT analysis posterobasal
59	MOTANTD	Num	4	212	f8Fq39A1B: Motion ANT D
58	MOTANTEX	Num	4	208	f8Fq39A1A: Motion ANT EX
60	MOTANTR	Num	4	216	f8Fq39A1C: Motion ANT R
57	MOTION	Num	4	204	f8Fq39: Patient motion interfered with s
62	MOTLAOD	Num	4	224	f8Fq39A2B: Motion LAO D
61	MOTLAOEX	Num	4	220	f8Fq39A2A: Motion LAO EX
63	MOTLAOR	Num	4	228	f8Fq39A2C: Motion LAO R
65	MOTLLATD	Num	4	236	f8Fq39A3B: Motion LLAT D
66	MOTLLATR	Num	4	240	f8Fq39A3C: Motion LLAT R
64	MOTLLATX	Num	4	232	f8Fq39A3A: Motion LLAT EX
79	NEWID	Num	8	8	Patient Identification
13	PERSADM	Num	4	56	f8Fq8: Persantine administered
14	PERSINF	Num	4	60	f8Fq8A: Persantine infusion
16	PERSORAL	Num	4	64	f8Fq8B: Oral persantine
15	PINFDOSE	Num	5	306	f8Fq8A1: Persantine infusion dose (mg)

(06FEB04--12:53)

*T3B form8f**The CONTENTS Procedure*

-----Alphabetic List of Variables and Attributes-----					
#	Variable	Type	Len	Pos	Label
17	PODOSE	Num	5	311	f8Fq8B1: Oral persantine dose (mg)
69	POSANTD	Num	4	252	f8Fq40A1B: Position ANT D
68	POSANTEX	Num	4	248	f8Fq40A1A: Position ANT EX
70	POSANTR	Num	4	256	f8Fq40A1C: Position ANT R
67	POSITION	Num	4	244	f8Fq40: Positioning difficulties
72	POSLAOD	Num	4	264	f8Fq40A2B: Position LAO D
71	POSLAOEX	Num	4	260	f8Fq40A2A: Position LAO EX
73	POSLAOR	Num	4	268	f8Fq40A2C: Position LAO R
75	POSLLATD	Num	4	276	f8Fq40A3B: Position LLAT D
76	POSLLATR	Num	4	280	f8Fq40A3C: Position LLAT R
74	POSLLATX	Num	4	272	f8Fq40A3A: Position LLAT EX
7	PROTHAL	Num	4	40	f8Fq5: Test according to protocol
1	REV	Num	8	0	Revision
50	SEPISC	Num	4	176	f8Fq37B: Reversible hypoperfusion septum
9	THALDOS2	Num	5	296	f8Fq6: Total dose of thallium (mCi)
10	THALEXER	Num	5	301	f8Fq7: Exercise time after injection
78	THALFEM	Num	4	288	f8Fq41A: Patient female
12	THALLIUM	Num	4	52	f8Fq5A (rev 0): Thallium 201 GI
23	THALNG	Num	4	76	f8Fq10: Nitroglycerin
11	THALPER	Num	4	48	f8Fq5 (rev 0): Thallium or Persantine
8	THALREAS	Num	4	44	f8Fq5A: Reason not according to protocol
6	THALTYP2	Num	4	36	f8Fq4: Time of test
5	THALTYPE	Num	4	32	f8Fq4 (rev 0): Time of test
24	THNGIV	Num	5	331	f8Fq10A1: Nitroglycerin IV dose (mcg IV)
25	THNGSL	Num	5	336	f8Fq10A2: Nitroglycerin SL dose (mg SL)
48	TLVDILAT	Num	4	168	f8Fq36: Transient LV dilatation
56	TWOISH	Num	4	200	f8Fq38B: 2 or more regions reversible hy

T3B form8f

Variable	Label	Value	N	%	<= 20
REV	Revision	0	211	13.0	
		1	271	16.7	
		2	902	55.6	
		3	238	14.7	
FMTYP	Form Type	TT01	1334	82.2	
		TT02	277	17.1	
		TT03	9	0.6	*
		TT04	2	0.1	*
IDTEST	f8Fq3 (rev 0): Identify test	.	449	27.7	
		1	1043	64.3	
		2	130	8.0	
IDTEST2	f8Fq3: Identify test	.	1384	85.3	
		1	217	13.4	
		2	19	1.2	*
		3	2	0.1	*
THALTYP2	f8Fq4: Time of test	.	482	29.7	
		1	937	57.8	
		2	175	10.8	
		3	9	0.6	*
		4	19	1.2	*
THALTYPE	f8Fq4 (rev 0): Time of test	.	1140	70.3	
		1	370	22.8	
		2	108	6.7	
		3	4	0.2	*

T3B form8f

Variable	Label	Value	N	%	<= 20
PROTTHAL	f8Fq5: Test according to protocol	.	1	0.1	*
		1	1563	96.4	
		2	58	3.6	
THALPER	f8Fq5 (rev 0): Thallium or Persantine	.	1411	87.0	
		1	211	13.0	
THALLIUM	f8Fq5A (rev 0): Thallium 201 GI	.	1411	87.0	
		1	211	13.0	
THALREAS	f8Fq5A: Reason not according to protocol	.	1564	96.4	
		1	2	0.1	*
		2	11	0.7	*
		3	12	0.7	*
		4	33	2.0	
PERSADM	f8Fq8: Persantine administered	.	212	13.1	
		1	149	9.2	
		2	1261	77.7	
PERSINF	f8Fq8A: Persantine infusion	.	1261	77.7	
		1	135	8.3	
		2	226	13.9	
PERSORAL	f8Fq8B: Oral persantine	.	1262	77.8	
		1	24	1.5	
		2	336	20.7	
AMINOPH	f8Fq8C: Aminophylline	.	1262	77.8	
		1	54	3.3	
		2	306	18.9	

T3B form8f

Variable	Label	Value	N	%	<= 20
ADENADM	f8Fq9: Adenosine	.	1385	85.4	
		1	3	0.2	*
		2	234	14.4	
IMAGE	f8Fq10 (rev 0): Thallium imaging complet	.	1140	70.3	
		1	355	21.9	
		2	127	7.8	
THALNG	f8Fq10: Nitroglycerin	1	40	2.5	
		2	1582	97.5	
IMPOST	f8Fq11A: Immed post-exercise scan	.	354	21.8	
		1	1260	77.7	
		2	8	0.5	*
IMDELAY	f8Fq11B: Delayed scan	.	354	21.8	
		1	1250	77.1	
		2	18	1.1	*
IMREST	f8Fq11C: Rest scan	.	354	21.8	
		1	182	11.2	
		2	1086	67.0	
ENDIHRT	f8Fq33: Enlarged heart	.	217	13.4	
		1	156	9.6	
		2	1249	77.0	

T3B form8f

Variable	Label	Value	N	%	<= 20
LAOUS	f8Fq34A1: LAO analysis upper septum	.	9	0.6	*
		1	103	6.4	
		2	71	4.4	
		3	102	6.3	
		4	1313	80.9	
		5	6	0.4	*
		6	18	1.1	*
LAOLS	f8Fq34A2: LAO analysis lower Septum	.	7	0.4	*
		1	85	5.2	
		2	73	4.5	
		3	136	8.4	
		4	1299	80.1	
		5	8	0.5	*
		6	14	0.9	*
LAOAPX	f8Fq34A3: LAO analysis apex	.	7	0.4	*
		1	252	15.5	
		2	135	8.3	
		3	150	9.2	
		4	1042	64.2	
		5	19	1.2	*
		6	17	1.0	*
LAOIL	f8Fq34A4: LAO analysis inferolateral	.	7	0.4	*
		1	172	10.6	
		2	76	4.7	
		3	88	5.4	
		4	1242	76.6	
		5	24	1.5	
		6	13	0.8	*

(06FEB04--12:53)

T3B form8f

Variable	Label	Value	N	%	<= 20
LAOPL	f8Fq34A5: LAO analysis posterolateral	.	7	0.4	*
		1	131	8.1	
		2	37	2.3	
		3	58	3.6	
		4	1355	83.5	
		5	21	1.3	
		6	13	0.8	*
ANTAB	f8Fq34B1: ANT analysis anterobasal	.	8	0.5	*
		1	35	2.2	
		2	29	1.8	
		3	38	2.3	
		4	1487	91.7	
		5	9	0.6	*
		6	16	1.0	*
ANTAL	f8Fq34B2: ANT analysis anterolateral	.	8	0.5	*
		1	67	4.1	
		2	45	2.8	
		3	57	3.5	
		4	1422	87.7	
		5	8	0.5	*
		6	15	0.9	*
ANTAPX	f8Fq34B3: ANT analysis apex	.	8	0.5	*
		1	288	17.8	
		2	115	7.1	
		3	98	6.0	
		4	1083	66.8	
		5	17	1.0	*
		6	13	0.8	*

T3B form8f

Variable	Label	Value	N	%	<= 20
ANTAS	f8Fq34B4: ANT analysis apical septum	.	8	0.5	*
		1	197	12.1	
		2	88	5.4	
		3	100	6.2	
		4	1205	74.3	
		5	11	0.7	*
		6	13	0.8	*
ANTIS	f8Fq34B5: ANT analysis inferoseptal	.	8	0.5	*
		1	163	10.0	
		2	54	3.3	
		3	75	4.6	
		4	1286	79.3	
		5	18	1.1	*
		6	18	1.1	*
LLATAB	f8Fq34C1: LLAT analysis anterobasal	.	11	0.7	*
		1	75	4.6	
		2	30	1.8	
		3	47	2.9	
		4	1418	87.4	
		5	9	0.6	*
		6	32	2.0	
LLATANT	f8Fq34C2: LLAT analysis anterior	.	10	0.6	*
		1	145	8.9	
		2	60	3.7	
		3	79	4.9	
		4	1282	79.0	
		5	14	0.9	*
		6	32	2.0	

T3B form8f

Variable	Label	Value	N	%	<= 20
LLATAPX	f8Fq34C3: LLAT analysis apex	.	9	0.6	*
		1	292	18.0	
		2	104	6.4	
		3	78	4.8	
		4	1090	67.2	
		5	18	1.1	*
		6	31	1.9	
LLATINF	f8Fq34C4: LLAT analysis inferior	.	8	0.5	*
		1	138	8.5	
		2	79	4.9	
		3	75	4.6	
		4	1285	79.2	
		5	19	1.2	*
		6	18	1.1	*
LLATPB	f8Fq34C5: LLAT analysis posterobasal	.	9	0.6	*
		1	161	9.9	
		2	46	2.8	
		3	60	3.7	
		4	1306	80.5	
		5	14	0.9	*
		6	26	1.6	
ABLUNG	f8Fq35: Abnormal lung uptake	.	3	0.2	*
		1	216	13.3	
		2	1403	86.5	
ABAMT	f8Fq35A: Lung uptake abnormality	.	1405	86.6	
		1	197	12.1	
		2	20	1.2	*

T3B form8f

Variable	Label	Value	N	%	<= 20
TLVDILAT	f8Fq36: Transient LV dilatation	.	214	13.2	
		1	78	4.8	
		2	1330	82.0	
ANTISC	f8Fq37A: Reversible hypoperfusion anteri	.	8	0.5	*
		1	201	12.4	
		2	1413	87.1	
SEPISC	f8Fq37B: Reversible hypoperfusion septum	.	8	0.5	*
		1	244	15.0	
		2	1370	84.5	
LATISC	f8Fq37C: Reversible hypoperfusion latera	.	8	0.5	*
		1	180	11.1	
		2	1434	88.4	
IAISC	f8Fq37D: Reversible hypoperfusion infero	.	8	0.5	*
		1	135	8.3	
		2	1479	91.2	
INFISC	f8Fq37E: Reversible hypoperfusion inferi	.	8	0.5	*
		1	286	17.6	
		2	1328	81.9	
APCISC	f8Fq37F: Reversible hypoperfusion non-co	.	8	0.5	*
		1	203	12.5	
		2	1411	87.0	
ALURED	f8Fq38A: Abnormal lung uptake & reversib	.	6	0.4	*
		1	145	8.9	
		2	1471	90.7	

T3B form8f

Variable	Label	Value	N	%	<= 20
TWOISH	f8Fq38B: 2 or more regions reversible hy	.	6	0.4	*
		1	359	22.1	
		2	1257	77.5	
MOTION	f8Fq39: Patient motion interfered with s	.	3	0.2	*
		1	46	2.8	
		2	1573	97.0	
MOTANTEX	f8Fq39A1A: Motion ANT EX	.	1619	99.8	
		1	3	0.2	*
MOTANTD	f8Fq39A1B: Motion ANT D	.	1618	99.8	
		1	4	0.2	*
MOTANTR	f8Fq39A1C: Motion ANT R	.	1621	99.9	
		1	1	0.1	*
MOTLAOEX	f8Fq39A2A: Motion LAO EX	.	1621	99.9	
		1	1	0.1	*
MOTLAOD	f8Fq39A2B: Motion LAO D	.	1620	99.9	
		1	2	0.1	*
MOTLAOR	f8Fq39A2C: Motion LAO R	.	1621	99.9	
		1	1	0.1	*
MOTLLATX	f8Fq39A3A: Motion LLAT EX	.	1604	98.9	
		1	18	1.1	*
MOTLLATD	f8Fq39A3B: Motion LLAT D	.	1597	98.5	
		1	25	1.5	

T3B form8f

Variable	Label	Value	N	%	<= 20
MOTLLATR	f8Fq39A3C: Motion LLAT R	.	1618	99.8	
		1	4	0.2	*
POSITION	f8Fq40: Positioning difficulties	.	3	0.2	*
		1	61	3.8	
		2	1558	96.1	
POSANTEX	f8Fq40A1A: Position ANT EX	.	1618	99.8	
		1	4	0.2	*
POSANTD	f8Fq40A1B: Position ANT D	.	1617	99.7	
		1	5	0.3	*
POSANTR	f8Fq40A1C: Position ANT R	.	1620	99.9	
		1	2	0.1	*
POSLAOEX	f8Fq40A2A: Position LAO EX	.	1603	98.8	
		1	19	1.2	*
POSLAOD	f8Fq40A2B: Position LAO D	.	1607	99.1	
		1	15	0.9	*
POSLAOR	f8Fq40A2C: Position LAO R	.	1615	99.6	
		1	7	0.4	*
POSLLATX	f8Fq40A3A: Position LLAT EX	.	1595	98.3	
		1	27	1.7	
POSLLATD	f8Fq40A3B: Position LLAT D	.	1594	98.3	
		1	28	1.7	

T3B form8f

Variable	Label	Value	N	%	<= 20
POSLLATR	f8Fq40A3C: Position LLAT R	.	1613	99.4	
		1	9	0.6	*
BREAST	f8Fq41: Breast attenuation	.	2	0.1	*
		1	314	19.4	
		2	1306	80.5	
THALFEM	f8Fq41A: Patient female	.	1301	80.2	
		1	291	17.9	
		2	30	1.8	

T3B form8f

Variable	Label	N	Percentile	Value	n	<= 20
THALDOS2	f8Fq6: Total dose of thallium (mCi)	1620	5	2	245	
			25	2.3	172	
			50	2.7	422	
			75	3	498	
			95	3.3	207	
			100	4.5	76	
THALEXER	f8Fq7: Exercise time after injection	1606	5	0	114	
			25	60	938	
			50	60	0	*
			75	90	186	
			95	120	327	
			100	720	41	
PINFDOSE	f8Fq8A1: Persantine infusion dose (mg)	135	5	30	8	*
			25	38	27	
			50	45	40	
			75	50	38	
			95	61.8	16	*
			100	74.3	6	*
PODOSE	f8Fq8B1: Oral persantine dose (mg)	24	5	300	21	
			25	300	0	*
			50	300	0	*
			75	300	0	*
			95	375	2	*
			100	600	1	*

T3B form8f

Variable	Label	N	Percentile	Value	n	<= 20
AMINDOSE	f8Fq8C1: Aminophylline dose (mg IV)	54	5	50	5	*
			25	75	12	*
			50	125	24	
			75	125	0	*
			95	325	11	*
			100	500	2	*
ADENDOSE	f8Fq9A: Adenosine dose (mg)	3	5	2.6	1	*
			25	2.6	0	*
			50	51.6	1	*
			75	65.6	1	*
			95	65.6	0	*
			100	65.6	0	*
ADENTIME	f8Fq9B: Adenosine infusion time (secs)	3	5	40	1	*
			25	40	0	*
			50	360	1	*
			75	420	1	*
			95	420	0	*
			100	420	0	*
THNGIV	f8Fq10A1: Nitroglycerin IV dose (mcg IV)	3	5	0	2	*
			25	0	0	*
			50	0	0	*
			75	60	1	*
			95	60	0	*
			100	60	0	*

T3B form8f

Variable	Label	N	Percentile	Value	n	<= 20
THNGSL	f8Fq10A2: Nitroglycerin SL dose (mg SL)	39	5	0.3	7	*
			25	0.4	24	
			50	0.4	0	*
			75	0.4	0	*
			95	0.8	8	*
			100	0.8	0	*

T3B form8f

Variable	Label	N	Mean	Std Dev	Minimum	Maximum
FM8FDAY	f8Fq2: Days to study	1622	20.0	41.8	1.0	840.0